6JH0 Stock Chart & Stats
€0.80
-€0.07(-6.74%)
At close: 4:00 PM EDT
€0.80
-€0.07(-6.74%)
Day’s Range― - ―
52-Week Range€0.81 - €2.12
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.01M
Enterprise Value€11.67M
Total Cash (Recent Filing)€17.96M
Total Debt (Recent Filing)€2.18M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 05, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding9,858,383
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.91Price Target Upside513.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Cell-therapy PlatformIN8bio is developing a differentiated gamma-delta T-cell platform spanning hematologic malignancies and solid tumors, including brain cancers. Combining tumor-targeting biology with genetic engineering could support broader applications and improve treatment persistence if clinical development succeeds.
Improving Loss TrajectoryMeaningful narrowing of net losses indicates improving cost control within the development-stage business. Although profitability remains distant, a lower recurring loss base can extend financial flexibility and allow more of the company’s resources to remain focused on advancing its clinical pipeline.
Modest LeverageLow debt relative to equity limits the burden of interest and mandatory repayments while clinical programs are still being developed. This provides greater balance-sheet flexibility than highly leveraged peers, even though the company continues to require funding for operations.
Bears Say
Pre-revenue Business ModelThe absence of product revenue means IN8bio has not yet demonstrated commercial demand or an internally funded operating model. Its near-term financial outlook remains dependent on clinical progress and eventual commercialization, leaving outcomes highly tied to development execution.
Persistent Cash BurnContinued negative operating and free cash flow shows that the business cannot currently finance its activities through operations. Even with improved burn, ongoing research spending will require external funding, which can constrain strategic flexibility and create financing dependence.
Capital ErosionThe substantial decline in equity and total assets reflects the cumulative effect of losses and cash consumption. Persistent capital erosion reduces the company’s financial cushion and can make future clinical investment increasingly dependent on raising additional capital.
IN8bio News
6JH0 FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was €0.81 and its highest was €2.12 in the past 12 months.
What is IN8bio’s market cap?
IN8bio’s market cap is €10.01M.
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Aug 06, 2026. The company reported -€0.223 earnings per share for the quarter, beating the consensus estimate of -€0.307 by €0.084.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -0.3.
How many shares outstanding does IN8bio have?
IN8bio has 9,858,383 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -€0.223 in its last earnings report, beating expectations of -€0.307. Following the earnings report the stock price went up 1.235%.
Which hedge fund is a major shareholder of IN8bio?
Currently, no hedge funds are holding shares in DE:6JH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IN8bio
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
6JH0 Stock 12 Month Forecast
Average Price Target
€4.91
▲(513.28% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
―
Aprea Therapeutics
―